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ABSTRACT 
N-methylpyrrole-N-methylimidazole (PI) polyamides are a class of DNA minor groove 
binders with DNA sequence-specificity. DNA-alkylating PI polyamide conjugates are 
attractive candidates as anticancer drugs acting through DNA damage and its 
subsequent inhibition of cell proliferation. One example is a chlorambucil-PI polyamide 
conjugate targeting the runt-related transcription factor (RUNX) family. RUNX1 has 
pro-oncogenic properties in acute myeloid leukemia, and recently the chlorambucil-PI 
polyamide conjugate was demonstrated to have anticancer effects. Herein, we apply 
another DNA-alkylating agent, seco-CBI, to target the consensus sequence of the RUNX 
family. Two types of CBI conjugates were prepared and their binding properties were 
characterized by Bind-n-Seq analysis using a high-throughput sequencer. The 
sequencing data were analyzed by two methods, MERMADE and our new MR (motif 
identification with a reference sequence), and the resultant binding motif logos were as 
predicted from the pairing rules proposed by Dervan et al. This is the first report to 
employ the MR method on alkylating PI polyamide conjugates. Moreover, cytotoxicity of 
conjugates 3 and 4 against a human non-small cell lung cancer, A549, were examined to 
show promising IC50s of 120 nM and 63 nM, respectively. These findings suggest seco-
CBI-PI polyamide conjugates are candidates for oncological therapy. 
 
1. Introduction 
There are a number of DNA-alkylating agents applied to cancer therapy,1,2 one of which 
is chlorambucil, a nitrogen mustard. The alkylation chemistry targets N7 of guanine and 
N3 of adenine, and interstrand crosslinking that specifically occurs between guanines of 
5′-GCC-3′/3′-CGG-5′.3 Although chlorambucil has been long used as a drug for chronic 
lymphatic leukemia and Hodgkin’s lymphoma, there are known adverse effects, such as 
nausea, vomiting, myelosuppression, diarrhea, and tremors, because specific organ 
toxicities derive from the high proliferative rates of bone-marrow cells and the 
epithelium of the gastrointestinal tract. Therefore, much effort has been put into 
alleviating these side effects. One of the strategies is to confer DNA sequence-specificity 
to the functional molecule. It can be assumed that delivery of an effector to a 
predetermined target would produce the desired biological results while reducing the off-
target effects, even if the carrier cannot restrict its destination to one site in the billions 
of base-pairs. N-methylpyrrole-N-methylimidazole (PI) polyamide is a well-
characterized synthetic molecule that binds in the minor groove and recognizes the DNA 
sequence following the pairing rule.4-7 PI polyamide with chlorambucil on its γ-turn was 
shown to alkylate and interstrand crosslink DNA in a sequence-specific manner in vitro 
and caused cell cycle arrest in the G2/M phase.8 The chlorambucil conjugate was later 
shown to regulate expression of histone H4 mRNA in various cancer cell lines and to 
produce a loss of tumorigenicity in mouse xenograft models of cancer.9 Recently PI 
polyamide-chlorambucil conjugate Chb-M′ was reported to show a remarkable 
improvement of overall survival periods in mouse models of acute myeloid leukemia 
compared with a DMSO control, chlorambucil, cytarabine (Cylocide), and PI polyamide 
control.10 Cytarabine is an anticancer drug for chemotherapy of acute and chronic 
myelogenous leukemia, acute lymphocytic leukemia, acute promyelocytic leukemia, and 
Hodgkin’s lymphoma. The target of Chb-M′ is the RUNX family, which is strongly 
associated with cancer development.11 Chb-M′ exerts its antitumor effects through 
inhibiting the binding of RUNX family members to the promoter regions of the p53 
degrading enzymes BCL11A and TRIM24, thereby inducing apoptosis. 
Inspired by these unprecedented results, we synthesized and evaluated seco-CBI-PI 
polyamide conjugates. seco-CBI (1-chloromethyl-5-hydroxy-1,2-dihydro-3H-benz[e]-
indole)12,13 is a synthetic DNA alkylator based on Duocarmycin A, and its conjugate with 
PI polyamide has long been investigated.14,15 While chlorambucil has a flexible alkyl 
linker, seco-CBI is conjugated with PI polyamide via a rigid indole linker, and its 
alkylation site would be defined more specifically. Another characteristic of seco-CBI 
conjugate is its greater cytotoxicity compared with the chlorambucil conjugate.16 In 2015, 
mutant KRAS suppression by seco-CBI conjugate resulted in tumor death in an 
oncogenic mutation-specific manner.17-19 These findings corroborate the significance of 
seco-CBI conjugate as a promising drug candidate. 
High-throughput sequencing is widely used for analysis of binding motifs of PI 
polyamides.20 One of the tested seco-CBI-PI polyamide conjugates is shown in Figure 1.21 
The Bind-n-Seq22 substrate DNA comprises 102 base pairs containing two adapters, a 
barcode, and 21 base-pair random sequences.18,19,21,23-25 The workflow starts from primer 
extension to prepare dsDNA containing random sequences, then a binding/alkylation 
reaction by the PI polyamide, affinity purification by exploiting the interaction between 
biotinylated PI polyamide and streptavidin magnetic beads, followed by emulsion PCR 
and sequencing. These properties are seen in vitro, but experiments targeting genomic 
DNA in vivo, Chem-Seq26, enabled biological discussions at gene levels.21,27,28 Here we 
investigated binding preferences of two PI polyamide conjugates using Bind-n-Seq 
analysis with a new MR (motif identification with a reference sequence) for the first time 
for alkylating conjugates as well as with the conventional MERMADE. In addition, their 
cytotoxicity against an A549 cell line was explored to expand the options for cancer 
treatment to targeting the RUNX family. 
 
 
Figure 1. A chemical structure (a) and schematic representation (b) of a biotinylated seco-
CBI-PI polyamide conjugate.21 
 
2. Materials and methods 
2.1. General 
Reagents and solvents were purchased from standard suppliers and used without further 
purification. Automated polyamide synthesis was performed on a PSSM-8 system 
(Shimadzu) on 30 μmol scale by Fmoc chemistry.29,30 HPLC purification was performed 
with a JASCO PU-2080 Plus pump, a UV-2075 Plus detector (254 nm), an MX-2080-32 
mixer and a DG-2080-54 degasser. A Chemcobond 5-ODS-H column (4.6 x 150 mm; 
Chemco Plus Scientific, Osaka, Japan) was used; the mobile phase was a gradient of 
acetonitrile with TFA (0.1%, v/v in water) at a flowrate of 1.0 mL min-1. ESI-TOFMS data 
were obtained on a BioTOF II (Bruker Daltonics). MALDI-TOFMS was performed on a 
microflex-KSII (Bruker Daltonics). NMR Spectra were recorded on a JEOL JNM ECA-
600 NMR spectrometer. The following abbreviations apply to spin multiplicity: s (singlet), 
d (doublet), t (triplet), m (multiplet). 
 
2.2. Synthesis 
2.2.1. Fmoc-Py-CO2H loading to 2-Cl-Trt resin 
Fmoc-Py-CO2H was loaded to 2-chlorotrityl chloride resin (2-Cl-Trt-Cl) resin mainly as 
previously reported,31 but N-methylpyrrolidone was chosen as a solvent during the 
coupling reaction instead of DMF for better solubility. 
 
2.2.2. Compound 5 
53 mg of 2-Cl-Trt-Cl resin (37.5 μmol/100 mg) loading AcIPII-(R)-BocHNγ-PP was shaken 
in a solution of 150 μL of hexafluoroisopropanol and 350 μL of CH2Cl2 for 3 h at room 
temperature. Then the solution was dripped into Et2O to obtain the crude solid (17.8 mg). 
HPLC retention time: 13.6 min (0-100% over 20 min). MALDI-TOFMS m/z calculated for 
C44H54N17O11+ [M + H]+ 996.418, found 996.271. 1H NMR (600 MHz, DMSO-d6): δ = 10.43 
(s, 1H), 10.26 (s, 1H), 9.93 (s, 1H), 9.89 (s, 1H), 9.86 (s, 1H), 9.40 (s, 1H), 8.21 (t, J = 5.8 
Hz, 1H), 7.63 (s, 1H), 7.52 (s, 1H), 7.42 (s, 1H), 7.40 (m, 2H), 7.18 (d, J = 2.0 Hz, 1H), 7.15 
(apparent s, 1H), 7.02 (d, J = 7.5 Hz, 1H), 6.91 (d, J = 1.4 Hz, 1H), 6.82 (d, J = 2.0 Hz, 
1H), 4.10 (m, 1H), 4.01 (s, 3H), 3.95 (s, 3H), 3.94 (s, 3H), 3.87 (s, 3H), 3.82 (s, 3H), 3.80 
(s, 3H), 3.29 (m, 2H), 2.02 (s, 3H), 1.91 (m, 1H), 1.79 (m, 1H), 1.39 (s, 9H). 
 
2.2.3. Compound 6 
0.86 mg (0.86 μmol) of 5 and 0.45 mg (2.0 eq, 1.7 μmol) of PyBOP were dissolved in 8.6 
μL of DMF, and to that solution was added 1.8 μL (12 eq, 10 μmol) of DIEA. After 
vortexing, 0.44 mg (1.0 eq, 0.86 μmol) of aminoindole-seco-CBI (TFA salt)32 was added 
and shaken for 2 h at room temperature. Et2O was added to workup and the obtained 
solid was proceeded to the next reaction without purification. HPLC retention time: 14.0 
min (0-100% over 20 min). 
 
2.2.4. Compound 7: 250 μL of 50% TFA in CH2Cl2 was added to the compound 6. 5 min 
later, Et2O was added to obtain the crude solid (1.43 mg). HPLC retention time: 11.4 min 
(0-100% over 20 min). MALDI-TOFMS m/z calculated for C61H61ClN20O10+ [M + H]+ 
1291.446, found 1291.482. 
 
2.2.5. Conjugate 1 
11 μL (1.1 mg, 1.1 μmol) of DMF solution of NHS-PEG12-Biotin, 1.0 μL (6.0 μmol) of DIEA 
and 8 μL of DMF were added to 1.43 mg of the crude compound 6 and shaken for 30 min 
at room temperature. The product solution was diluted by DMF and injected into HPLC 
for purification to yield 1.88 mg of the product powder. HPLC retention time: 12.0 min 
(0-100% over 20 min), 10.3 min (30-90% over 20 min). MALDI-TOFMS m/z calculated for 
C98H128ClN23NaO25S+ [M + Na]+ 2116.875, found 2116.876. 
 
2.2.6. Compound 8 
80 mg of 2-chlorotrityl chloride resin (2-Cl-Trt-Cl) resin (37.5 μmol/100 mg) loading 
AcIPII-(R)-BocHNγ-PPP was shaken in a solution of 300 μL of hexafluoroisopropanol and 
700 μL of CH2Cl2 for 3 h at room temperature. Then the solution was dripped into Et2O 
to obtain the crude solid (28.3 mg).HPLC retention time: 13.4 min (0-100% over 20 min). 
MALDI-TOFMS m/z calculated for C50H60N19O12+ [M + H]+ 1118.466, found 1118.357. 1H 
NMR (600 MHz, DMSO-d6): δ = 10.43 (s, 1H), 10.26 (s, 1H), 9.94 (s, 1H), 9.91 (s, 1H), 
9.884 (s, 1H), 9.877 (s, 1H), 9.40 (s, 1H), 8.22 (t, J = 5.5 Hz, 1H), 7.63 (s, 1H), 7.53 (s, 1H), 
7.42 (s, 1H), 7.41 (d, J = 2.0 Hz, 1H), 7.39 (d, J = 1.3 Hz, 1H), 7.22 (d, J = 2.1 Hz, 1H), 
7.18 (d, J = 1.4 Hz, 1H), 7.16 (apparent s, 1H), 7.04 (d, J = 1.4 Hz, 1H), 7.02 (d, J = 7.6 
Hz, 1H), 6.92 (d, J = 2.1 Hz, 1H), 6.84 (d, J = 2.0 Hz, 1H), 4.11 (m, 1H), 4.01 (s, 3H), 3.95 
(s, 3H), 3.94 (s, 3H), 3.87 (s, 3H), 3.834 (s, 3H), 3.831 (s, 3H), 3.82 (s, 3H), 3.29 (m, 2H), 
2.02 (s, 3H), 1.92 (m, 1H), 1.79 (m, 1H), 1.40 (s, 9H). 
 
2.2.7. Compound 9 
1.22 mg (1.09 μmol) of 8 and 1.1 mg (2.0 eq, 2.2 μmol) of PyBOP were dissolved in 10 μL 
of DMF, and to that solution was added 2.1 μL (11 eq, 12 μmol) of DIEA. 10 min later, 
0.55 mg (1.0 eq, 1.1 μmol) of aminoindole-seco-CBI (TFA salt)32 was added and shaken 
for 5 h at room temperature. Et2O was added to workup and though the property of the 
product was oily, it was proceeded to the next reaction without purification. HPLC 
retention time: 14.8 min (0-100% over 20 min). MALDI-TOFMS m/z calculated for 
C72H75ClN22NaO13+ [M + Na]+ 1513.547, found 1513.561. 
 
2.2.8. Compound 10 
320 μL of 50% TFA in CH2Cl2 was added to the compound 9. 30 min later, Et2O was 
added to obtain the dark brown powder (1.30 mg). HPLC retention time: 12.9 min (0-
100% over 20 min). MALDI-TOFMS m/z calculated for C67H68ClN22O11+ [M + H]+ 
1391.512, found 1391.522. 
 
2.2.9. Conjugate 2 
8.9 μL (0.89 mg, 0.95 μmol) of DMF solution of NHS-PEG12-Biotin, 0.89 μL (5.2 μmol) of 
DIEA and 8.9 μL of DMF were added to 1.30 mg of the crude compound 10 and shaken 
for 1 h at room temperature. The product solution was diluted by DMF and injected into 
HPLC for purification. This product was purified again to yield 0.40 mg of the product 
powder. HPLC retention time: 12.0 min (0-100% over 20 min), 11.0 min (30-90% over 20 
min). MALDI-TOFMS m/z calculated for C98H128ClN23NaO25S+ [M + Na]+ 2238.923, 
found 2238.973. 
 
2.2.10. Compound 11 
AcIPII-γ-PP Trt resin was synthesized in a stepwise reaction by the Fmoc solid-phase 
protocol. Subsequently, the resin was treated with CH2Cl2 (350 μL) and 30% 
hexafluoroisopropanol (150 μL) at rt for 3 h. After filtration, the filtrate was evaporated 
and CH2Cl2 (400 μL), MeOH (100 μL) and Et2O (5 mL) were added. The solution was 
sonicated and the target product was collected. A weight of the target product was 16.9 
mg (19 μmol). MALDI-TOFMS m/z calcd for C39H45N16O9+ [M + H]+ 881.355, found 
881.371. 1H NMR (600 MHz, DMSO-d6): δ =10.43 (s, 1H), 10.27 (s, 1H), 9.88 (s, 1H), 9.82 
(s, 2H), 9.38 (s, 1H), 8.29 (t, J = 5.8 Hz, 1H), 7.63 (s, 1H), 7.52 (s, 1H), 7.43 (s, 1H), 7.40 
(d, J = 1.4 Hz, 1H), 7.39 (s, 1H), 7.18 (d, J = 2.1 Hz, 1H), 7.14 (d, J = 1.4 Hz, 1H), 6.85 
(apparent s, 1H), 6.81 (s, 1H), 4.01 (s, 3H), 3.96 (s, 3H), 3.95 (s, 3H), 3.87 (s, 3H), 3.81 (s, 
6H), 3.27 (m, 2H), 2.28 (t, J = 7.6 Hz, 2H), 2.02 (s, 3H), 1.82 (m, 2H). 
 
 
2.2.11. Conjugate 3 
Compound 11 (4.0 mg, 4.6 μmol, 1.0 eq.), PyBOP (4.8 mg, 9.2 μmol, 2.0 eq.) and DIEA 
(4.8 μL, 28 μmol, 6.0 eq.) in DMF (10 µL) were stirred for 5 min. Then H2N-indole−seco-
CBI (3.6 mg, 9.2 μmol, 2.0 eq.) in DMF (5 µL) was added and stirred at rt for 1 h. After 
consumption of activated ester was confirmed by HPLC analysis. Et2O was added to the 
mixture and resultant was collected by centrifuged, and washed by Et2O and CH2Cl2. A 
weight of the target product was 2.8 mg (2.2 μmol, 49% yield) after HPLC purification. 
The retention time was 11.1 min (0.1% TFA containing 36−56% acetonitrile over a linear 
gradient for 30 min at a flow rate of 1.0 mL/min detected at 254 nm). ESI-TOFMS m/z 
calcd for C61H62ClN19O102+ [M + 2H]2+ 627.7302, found 627.7289. 
 
2.2.12. Compound 12 
AcIPII-γ-PPP Trt resin was synthesized in a stepwise reaction by the Fmoc solid-phase 
protocol. Subsequently, the resin was treated with CH2Cl2 (700 μL) and 30% 
hexafluoroisopropanol (300 μL) at rt for 3 h. After filtration, the filtrate was evaporated 
and CH2Cl2 (800 μL), MeOH (200 μL) and Et2O (5 mL) were added. The solution was 
sonicated and the target product was collected. A weight of the target product was 29.0 
mg (29 μmol). MALDI-TOFMS m/z calcd for C45H51N18O10+ [M + H] + 1003.403, found 
1003.422. 1H NMR (600 MHz, DMSO-d6): δ =10.43 (s, 1H), 10.27 (s, 1H), 9.89 (s, 1H), 
9.88 (s, 2H), 9.83 (s, 1H), 9.39 (s,1H), 8.29 (t, J = 6.2 Hz, 1H), 7.63 (s, 1H), 7.52 (s, 1H), 
7.43 (s, 1H), 7.42 (d, J = 1.4 Hz, 1H), 7.40 (d, J = 2.1 Hz, 1H), 7.22 (d, J = 1.4 Hz, 1H), 
7.18 (d, J = 1.3 Hz, 1H), 7.16 (d, J = 2.0 Hz, 1H),7.04 (d, J = 2.0 Hz, 1H), 6.86 (d, J = 1.4 
Hz, 1H), 6.84 (d, J = 2.0 Hz, 1H), 4.01 (s, 3H), 3.96 (s, 3H), 3.95 (s, 3H), 3.87 (s, 3H), 3.83 
(s, 3H), 3.824 (s, 3H), 3.817 (s, 3H), 3.27 (m, 2H), 2.28 (t, J = 7.5 Hz, 2H), 2.02 (s, 3H), 
1.82 (m, 2H). 
 
2.2.13. Conjugate 4 
Compound 12 (3.4 mg, 3.4 μmol, 1.0 eq.), PyBOP (3.5 mg, 6.8 μmol, 2.0 eq.) and DIEA 
(3.6 μL, 20 μmol, 6.0 eq.) in DMF (10 µL) were stirred for 5 min. Then H2N-indole−seco-
CBI (1.6 mg, 4.1 μmol, 1.2 eq.) in DMF (3 µL) was added and stirred at rt for 1 h. After 
consumption of activated ester was confirmed by HPLC analysis. Et2O was added to the 
mixture and resultant was collected by centrifuged, and washed by Et2O and CH2Cl2. A 
weight of the target product was 0.5 mg (0.36 μmol, 21% yield) after HPLC purification. 
The retention time was 15.7 min (0.1% TFA containing 30−70% acetonitrile over a linear 
gradient for 30 min at a flow rate of 1.0 mL/min detected at 254 nm). MALDI-TOFMS 
m/z calcd for C67H67ClN21O11+ [M + H]+ 1376.501, found 1376.505. 
 
2.3. Bind-n-Seq assay 
2.3.1. Primer extension 
The ODN1 (5’-CCATCTCATCCCTGCGTGTCTCCGACTCAG CTAAGGTAAC 
N21 ATCACCGACTGCCCATAGAGAGGAAAGCGGAGGCGTAGTGG-3’), ODN2 (5’-
CCATCTCATCCCTGCGTGTCTCCGACTCAG TAAGGAGAAC N21 
ATCACCGACTGCCCATAGAGAGGAAAGCGGAGGCGTAGTGG-3’) and ODN3 (5’-
CCATCTCATCCCTGCGTGTCTCCGACTCAG AAGAGGATTC N21 
ATCACCGACTGCCCATAGAGAGGAAAGCGGAGGCGTAGTGG-3’) were purchased 
from Sigma-Aldrich. Ion Torrent adapter A1 is 5’- 
CCATCTCATCCCTGCGTGTCTCCGACTCAG-3’, P1 adapter is 5’- 
ATCACCGACTGCCCATAGAGAGGAAAGCGGAGGCGTAGTGG-3’. Ion Xpress 
Barcodes are 5’-CTAAGGTAAC-3’, 5’-TAAGGAGAAC-3’ and 5’-AAGAGGATTC-3’, for 
ODN1, 2 and 3, respectively. N21 is the random sequence to be analyzed which is expected 
to contain the binding sites of the test PIP conjugate. Primer extensions for preparation 
of duplex of the ODNs were performed in a 25 μL reaction volume and consisting of 5.25 
μL nuclease-free water, 12.5 μL GoTaq Green Master Mix, 4.5 μL of 50 μM primer (5’-
CCACTACGCCTCCGCTTTCCTCTCTA-3’), 1.25 μL of 10 mM MgCl2 and 1.5 μL of 50 μM 
template ODN 1, 2 or 3. The thermal condition was programmed for 2 min at 95 oC, 1 
min, followed by 1 min at 63 oC, 4 min at 72 oC in ProFlex PCR System (Thermo Fisher 
Scientific). dsODNs1 and 2 were used as the substrates for conjugate 1 and 2, 
respectively. dsODN3 was prepared as the input control during “Amplification” step 
described later, and proceeded to “Affinity purification”. 
 
2.3.2. Determination of PIP concentration 
Molar extinction coefficients ε of the PIP conjugate in DMF solution at around 305 nm 
were calculated as 7.64 x 104 and 8.63 x 104, respectively33 and their concentrations were 
determined by the Lambert-Beer law. PIP conjugate was dissolved in DMSO and ε in 
DMSO was assumed to be same as in DMF. Absorbance was measured by NanoDrop 
(ND-1000, Thermo Fisher Scientific). 1.0 μM of DMSO solution of PIP conjugate was 
diluted to 100 nM by TKMC solution (10 mM Tris-HCl pH 7.0, 10 mM KCl, 10 mM MgCl2 
and 5 mM CaCl2). 
 
2.3.3. Binding reaction 
25 μL of that 100 nM solution was added to 25 μL of the primer extended solution, and 
the resulting solution was incubated for 16 h at rt. 
 
2.3.4. Enrichment reactions 
The procedure was based on a previous paper.25 After the supernatant was removed, 
Streptavidin M-280 Dynabeads (50 μL, 0.5 mg/sample) were washed with 50 μL/sample 
of BSA solution (3.5 mg/mL in PBS) for 10 min twice, then with 50 μL/sample with calf 
thymus DNA solution (0.5 mg/mL in water) for 90 min. The supernatant was discarded 
and the beads were treated with 100 μL/sample of binding and washing buffer (5 mM 
Tris-HCl pH 7.5, 0.5 mM EDTA and 1 M NaCl) for 1 min thrice. Resuspension of 50 
μL/sample of the beads in the binding and washing buffer was divided up among samples. 
The sample solutions from binding reaction were added to the buffer and incubated at 
room temperature for 1 h with pipetting every 10 min. The supernatant was removed 
and the beads were washed with 0.5 mL of binding and washing buffer for 5 min, then 
with 0.5 mL of TKMC solution for 10 min twice. Enriched DNA was recovered by heating 
in 100 μL of elution buffer (2% SDS, 100 mM NaHCO3 and 3 mM biotin) at 300 rpm at 65 
oC for 7 h followed by magnetic separation. 
 
2.3.5. Amplification 
A PCR reaction was performed in a 25 μL volume using Ion Plus Fragment Library Kit 
(Thermo Fisher Scientific) following the manufacturer’s instructions but the cycle 
number was set at 15. 
 
2.3.6. Affinity purification 
PCR products were purified by Agencourt AMPure XP beads (Beckman Coulter) 
following the manufacturer’s instructions. The quality and concentration were analyzed 
by Agilent 2100 Bioanalyzer and High Sensitivity DNA Kit (Agilent Technologies). Due 
to a high concentration of the input control, it was diluted by a factor of 10 before loaded 
on the chip. 
 
2.3.7. Emulsion PCR 
Emulsion PCR of all the three sample was performed at a time on the Ion OneTouch 2 
System (Thermo Fisher Scientific) using the Ion PGM Hi-Q View OT2 Kit. The library 
concentrations from both dsODN1 and 2 were 8 pM based on the results from Bioanalyzer. 
As that from dsODN3 showed a relatively broad peak, its 20 pM was mixed with the 
other two. The resulting beads were enriched by Ion OneTouch 2 ES. 
 
2.3.8. Sequencing 
The enriched libraries on Ion 318 Chip v2 BC were sequenced by Ion PGM System 
(ThermoFisher Scientific) using Ion PGM Hi-Q View Sequencing Kit. 
 
2.3.9. Data analysis 
Torrent Suite software 5.2.2 was applied to obtain fastq files and the following analyses 
were done by “Terminal” software in Ubuntu. The raw data were reanalyzed to fit into 
our purpose by setting the minimum read length as 8, then converted to fasta files 
(script: awk ‘NR % 4 == 1 {print “>” $0} NR % 4 == 2 {print $0}’). These fasta files were 
trimmed to pick up only sequences with 21 bases and to remove reads which contained 
three continuous bases such as AAA (PRINSEQ script34: perl prinseq-lite.pl -min_len 21 
-max_len 21 -custom_params “A 3;T 3;G 3;C 3” -fasta). PRINSEQ is available at 
https://sourceforge.net/projects/prinseq/files/standalone/. A particular number of random 
reads were subsampled so that the numbers of both the sample and input control would 
be the same (script: perl fasta-subsample <sequences> <count>). “fasta-subsample” is 
one of the other utilities in the MEME Suite available at http://meme-
suite.org/doc/download.html?man_type=web. 7-mers were identified from sequences of 
the sample and control (MERMADE script: perl kmer_counter.pl -k 7). Enrichment 
values were acquired by comparison of the sample and control data (MERMADE script: 
perl kmer_selector.pl -d -r 1.5). The default threshold of enrichment was 2, but as the 
resulting sequences were too few to proceed to motif analysis, it was lowered to 1.5. 
Mermade matrices were generated (MERMADE scripts: perl mermade.pl), and 
visualized as logos by enoLOGOS35 (http://www.benoslab.pitt.edu/cgi-
bin/enologos/enologos.cgi). MERMADE scripts are available from the Korf lab 
(http://korflab.ucdavis.edu/Datasets/BindNSeq/). 
 
2.3.10. Updated MR method for Bind-n-Seq analysis 
The MR method reported previously24 was slightly modified in order to detect sliding of 
sequences from their reference more accurately. To detail, sliding was judged by counting 
the match bases between the reference sequence and the sample: the reference sequence 
is fixed, the sample sequence was overlapped base by base from left end to right end, and 
the match bases are counted at each disposition. Its complementary sequence is 
examined in the same way at the same time. The location to achieve the maximum 
number of match bases is identified as the correct disposition. If that location overlaps 
completely with the reference sequence, the read is considered to be fit, and otherwise 
slid. In the original MR method, a sequenced read was judged as fit if either a sample or 
its complementary sequence overlaps completely, but this updated MR method finds out 
the best location from the sample and the complementary together. Thus, if the slid-state 
complementary sequence scores higher than the fit-state original one, that read will be 
judged as slid and excluded from the list to compose the resultant motif. This 
modification should attain more reasonable representation. This program and its source 
code are available from H. Sugiyama. 
 
2.4. Cytotoxicity Assay 
Human lung adenocarcinoma epithelial A549 cells (JCRB0076, establisher: Giard, D.) 
were obtained from JCRB cell bank. A549 was cultured in Dulbecco’s Modified Eagle 
Medium (DMEM; Thermo Fisher) with 10% of FBS and 1% of L-glutamine. The cells 
were maintained at 37 oC in humidified atmosphere of 95% air and 5% CO2. Colorimetric 
assays using cell count reagent SF containing WST-8 (Nacalai tesque) were performed 
on 96-well plates. A 100 μL amount of cell suspension was added to each well (5000 
cells/well) and incubated at 37 oC for 24 h. seco-CBI-PI polyamide conjugates were 
dissolved in DMSO, and 100 μL of each solution in the medium (final DMSO 
concentration was 0.2%) was added. After treatment for 48 h, removed the medium 
which contained conjugates and 100 μL of mixture of cell count reagent SF and medium 
(SF:medium = 1:10) was added to each well and incubated at 37 oC. Absorbance was then 
measured at 450 nm using a SpectraMax M2e microplate reader (Molecular Devices) 
after 1 h treatment. 
 
3. Results and Discussion 
3.1. Design and synthesis of conjugates 
The sequences of conjugates 1–4 were designed based on the target site of Chb-M′ 
(chlorambucil-β-IPII-γ-PPPP-Dp)10, 5′-WCCWCW-3′, and the structure of conjugates 1 
and 3 mimicked AcIIPP-γ-II-indole-seco-CBI.21 For the Bind-n-Seq analysis, biotinylated 
seco-CBI-PI polyamide conjugates 1 and 2 were synthesized (Scheme 1). 2-Cl-Trt-Cl resin 
was used for P-loading.31 After completion of couplings, the resin was treated with 
hexafluoroisopropanol for cleavage and indole-seco-CBI was coupled. As the pyrrole at 
the C-terminus experienced decarboxylation faster than deprotection when treated with 
20% TFA in CH2Cl2, indole-seco-CBI was coupled, then the Boc group was removed by 
TFA. The last step was biotinylation to yield conjugates 1 and 2. Conjugates 3 and 4 for 
cytotoxicity assays were prepared using a similar procedure (Scheme 1). 
 
Scheme 1. Synthesis of conjugates 1–4. Reagents and conditions: (i) 30% 
hexafluoroisopropanol, CH2Cl2; (ii) indole-seco-CBI, PyBOP, DIEA, DMF; (iii) 50% TFA, 
CH2Cl2; (iv) NHS-PEG12-biotin, DIEA, DMF. 
 
3.2. Bind-n-Seq analysis 
3.2.1. MERMADE method 
The sliding window for identifying binding motifs was set at 7-mer for both conjugates 
for comparison. Conjugates 1 and 2 showed motif logos successfully following the pairing 
rules4-7 and the expected adenine at the alkylating site (Figure 2): 5′-WCCWCAN-3′ and 
5′-WCCWCWA-3′, respectively (W = A or T; N = A, T, G or C). As the binding motif of 
conjugate 1 is only 6-mer, the seventh base was out of that 6-mer and is reasonably CTGA. 
The sixth alkylation base of conjugate 1 was not exclusively A, while the alkylation bases 
of conjugate 2 are exclusive. This finding may suggest the lower alkylating activity of 
conjugate 1. The enrichment values are calculated as ratios of sample vs input control, 
but the reason for low enrichment values for 1 is unknown. 
 
3.2.2. MR method24 
This analytical method was developed in 2016 to compensate for weakness of the 
MERMADE method. On one hand as discussed in that paper, the MERMADE method 
has a tendency to overestimate the first-ranked sequence because it takes sequences 
with only one mismatch compared from that central sequence into consideration, 
resulting in unexpected selectivity of A or T. On the other hand, as the MR method picks 
up sequences from top to a designated rank, the representation becomes fairer to show 
A and T with comparable sizes. After a slight modification of the reported MR program 
in order to detect sliding of sequences from their reference more accurately, this feature 
was observed in this study as well (Figure 2). Still, it is noteworthy that the seventh base 
in motif of conjugate 2 was exclusive A, suggesting that this base was alkylated by seco-
CBI. This is the first time to apply the MR method to analysis of alkylating PI polyamide 
conjugates. 
 
Figure 2. Bind-n-Seq results obtained with conjugates 1 (a) and 2 (b). The top panel 
shows schematic representations of the conjugates, the middle panel motif logos by the 
MERMADE or MR method, and the bottom panel, tables of sequences numbered in order 
of enrichment values. The results by the MR method were obtained from top 20 excluding 
slid sequences, and the reference sequences were 5’-WCCWCAN-3’ and 5’-WCCWCWCA-
3’ for 1 and 2, respectively. 
 
3.3. Cytotoxicity 
To explore the utility of these seco-CBI-PI polyamide conjugates, we evaluated the 
cytotoxicity of conjugates 3 and 4 against A549 cells, a human lung carcinoma cell line, 
using the WST assay, and determined the IC50 values (the concentration required for 
50% inhibition of cell-growth) of each conjugate (Figure 3). Conjugate 4 showed higher 
cytotoxicity than conjugate 3. Nevertheless, both of the PIP-CBI conjugates showed IC50 
values at submicromolar concentrations. Chb-M′ targeting the same sequence as 
conjugates 3 and 4 was cytotoxic for A549 cells at micromolar concentrations.10 These 
results suggest that seco-CBI-PI polyamide conjugates had higher cytotoxicity than the 
chlorambucil-PI polyamide conjugate. 
 
Figure 3. IC50 values of seco-CBI-PI polyamide conjugates against A549 cells. 
 
4. Conclusions 
As RUNX-targeting Chb-M′ enabled leukemia mouse models to survive much longer 
than the DMSO control, chlorambucil, the anticancer drug cytarabine, and PI polyamide 
control, CBI-version of PI polyamide conjugates were designed, synthesized, and 
characterized in vitro. Bind-n-Seq analysis with both the MERMADE and MR methods 
indicated that the two conjugates 1 and 2 had high sequence-specificity and alkylating 
activity. IC50 values for the A549 cancer cell line of around 100 nM were lower than those 
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